3.85

3.22% 0.12

Mannkind Corp (MNKD)

Overview News Price History Option Chain Financials Why MNKD Down? Discussions Forecast Stock Split

Mannkind Corp stock is traded at $3.85, with a volume of 2.85M. It is up +3.22% in the last 24 hours and down -0.77% over the past month. MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Previous Close:

$3.73

Open:

$3.74

24h Volume:

2.85M

Relative Volume:

0.56

Market Cap:

$1.24B

Revenue:

$360.78M

Net Income/Loss:

$-23.91M

P/E Ratio:

-49.30

EPS:

-0.0781

Net Cash Flow:

$13.07M

1W Performance:

-6.33%

1M Performance:

-0.77%

6M Performance:

-31.98%

1Y Performance:

+4.05%

1-Day Range:

$3.69

$3.85

1-Week Range:

$3.63

$4.08

52-Week Range:

$2.23

$6.51

Mannkind Corp Stock (MNKD) Company Profile

Name

Mannkind Corp

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

818-661-5000

Address

1 CASPER STREET, DANBURY, CA

Employee

592

Twitter

@MannKindCorp

Next Earnings Date

2026-08-05

Latest SEC Filings

MNKD's Discussions on Twitter

Compare MNKD vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNKD Mannkind Corp	3.85	1.24B	360.78M	-23.91M	13.07M	-0.0781
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-27-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-24-25	Initiated	Truist	Buy
Nov-13-25	Initiated	Leerink Partners	Outperform
Oct-20-25	Initiated	Wells Fargo	Overweight
Oct-10-25	Initiated	Leerink Partners	Outperform
Jul-16-25	Resumed	H.C. Wainwright	Buy
Apr-10-25	Initiated	Mizuho	Outperform
Feb-10-25	Initiated	Wedbush	Outperform
Dec-20-24	Initiated	Wells Fargo	Overweight
Dec-19-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Sep-09-24	Resumed	Leerink Partners	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Oct-10-23	Initiated	Wedbush	Outperform
May-14-21	Initiated	RBC Capital Mkts	Sector Perform
Dec-24-19	Initiated	Oppenheimer	Outperform
Oct-25-19	Initiated	Cantor Fitzgerald	Overweight
May-14-19	Initiated	BTIG Research	Buy
Mar-04-19	Initiated	SVB Leerink	Outperform
Feb-22-19	Initiated	SVB Leerink	Outperform
Feb-28-18	Downgrade	Maxim Group	Hold → Sell
Nov-01-17	Downgrade	Maxim Group	Buy → Hold
Oct-10-17	Initiated	H.C. Wainwright	Buy
Oct-06-17	Reiterated	Maxim Group	Buy
Aug-11-17	Initiated	Maxim Group	Buy
May-10-16	Reiterated	Piper Jaffray	Underweight
May-10-16	Reiterated	RBC Capital Mkts	Underperform
Jan-06-16	Reiterated	Piper Jaffray	Underweight
Jan-06-16	Reiterated	RBC Capital Mkts	Underperform
Nov-04-15	Downgrade	RBC Capital Mkts	Outperform → Underperform
Sep-09-15	Downgrade	Piper Jaffray	Neutral → Underweight
Aug-03-15	Reiterated	RBC Capital Mkts	Outperform
May-11-15	Downgrade	JP Morgan	Neutral → Underweight
May-11-15	Reiterated	MLV & Co	Hold
Apr-16-15	Reiterated	RBC Capital Mkts	Outperform

View All

Mannkind Corp Stock (MNKD) Latest News

Aug 14, 2026

Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake - Stock Titan

Aug 14, 2026

Research Analysts Set Expectations for MannKind Q3 Earnings - MarketBeat

Aug 14, 2026

MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits

Aug 14, 2026

Aug 13, 2026

MannKind FY2029 EPS Estimate Decreased by HC Wainwright - MarketBeat

Aug 13, 2026

MannKind gains FDA approvals, boosting growth p... - Pluang

Aug 13, 2026

Aug 11, 2026

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - Taiwan News

Aug 11, 2026

Mannkind director Steven Binder sells $158,547 in common stock By Investing.com - Investing.com UK

Aug 11, 2026

Aug 10, 2026